Published in Nat Med on August 12, 2002
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol (2008) 11.02
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol (2008) 2.68
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol (2007) 2.67
Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol (2014) 2.59
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med (2013) 2.01
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med (2005) 1.87
Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 1.85
A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol (2004) 1.62
Novel anti-inflammatory--pro-resolving mediators and their receptors. Curr Top Med Chem (2011) 1.61
Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol (2013) 1.59
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest (2012) 1.57
Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus. Pediatr Crit Care Med (2012) 1.51
Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med (2008) 1.45
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med (2014) 1.44
A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation. Proc Natl Acad Sci U S A (2004) 1.42
Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol (2009) 1.42
Resolution of acute inflammation in the lung. Annu Rev Physiol (2013) 1.42
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci (2009) 1.42
Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J Biol Chem (2009) 1.36
Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J (2011) 1.23
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J (2007) 1.20
NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol (2011) 1.13
Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J (2007) 1.12
Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res (2010) 1.08
Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol (2008) 1.08
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front Immunol (2012) 1.06
Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids. Annu Rev Physiol (2013) 1.05
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (2013) 1.05
Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol (2014) 1.04
Resolution of inflammation in asthma. Clin Chest Med (2012) 1.02
Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids (2008) 0.99
Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res (2010) 0.99
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol (2015) 0.99
Lipid mediators as agonists for the resolution of acute lung inflammation and injury. Am J Respir Cell Mol Biol (2006) 0.99
The role of pro-resolution lipid mediators in infectious disease. Immunology (2014) 0.98
Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm (2015) 0.97
Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes. J Immunol (2008) 0.95
Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. Prostaglandins Leukot Essent Fatty Acids (2009) 0.93
Gene expression profiling in human asthma. Proc Am Thorac Soc (2007) 0.92
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol (2012) 0.92
Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation. Front Immunol (2014) 0.91
5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Biochem J (2006) 0.90
Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am (2012) 0.88
Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis (2009) 0.87
Potential effects of medicinal plants and secondary metabolites on acute lung injury. Biomed Res Int (2013) 0.86
Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation. PLoS One (2012) 0.85
Adam8 limits the development of allergic airway inflammation in mice. J Immunol (2013) 0.84
Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways. Front Immunol (2012) 0.84
Platelet activation during allergic inflammation. Inflammation (2007) 0.84
Aspirin and decreased adult-onset asthma: randomized comparisons from the physicians' health study. Am J Respir Crit Care Med (2006) 0.84
The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. Prostaglandins Leukot Essent Fatty Acids (2010) 0.84
Lipoxin A₄ modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur J Immunol (2014) 0.84
Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med (2013) 0.83
Lipoxin B₄ promotes the resolution of allergic inflammation in the upper and lower airways of mice. Mucosal Immunol (2014) 0.82
Innate immunity is a key factor for the resolution of inflammation in asthma. Eur Respir Rev (2015) 0.82
Roles of lipoxin A4 receptor activation and anti-interleukin-1β antibody on the toll-like receptor 2/mycloid differentiation factor 88/nuclear factor-κB pathway in airway inflammation induced by ovalbumin. Mol Med Rep (2015) 0.82
Targeting pro-resolution pathways to combat chronic inflammation in COPD. J Thorac Dis (2014) 0.81
Molecular circuits of resolution in airway inflammation. ScientificWorldJournal (2010) 0.80
'Good' lipids for asthma. Nat Med (2002) 0.80
Chemical mediators and the resolution of airway inflammation. Allergol Int (2008) 0.80
Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. Semin Immunopathol (2016) 0.79
Resolvin D1 protects podocytes in adriamycin-induced nephropathy through modulation of 14-3-3β acetylation. PLoS One (2013) 0.79
Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop. F1000Prime Rep (2015) 0.79
Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium. Am J Physiol Cell Physiol (2011) 0.79
Phagocytic clearance of apoptotic cells: role in lung disease. Expert Rev Respir Med (2008) 0.78
Arachidonic acid intake and asthma risk in children and adults: a systematic review of observational studies. J Nutr Sci (2014) 0.78
15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth. Mol Hum Reprod (2015) 0.78
At the bedside: the emergence of group 2 innate lymphoid cells in human disease. J Leukoc Biol (2014) 0.77
An oily, sustained counter-regulatory response to TB. J Clin Invest (2005) 0.77
From bedside to bench to clinic trials: identifying new treatments for severe asthma. Dis Model Mech (2013) 0.77
The formylpeptide receptor 2 (Fpr2) and its endogenous ligand cathelin-related antimicrobial peptide (CRAMP) promote dendritic cell maturation. J Biol Chem (2014) 0.77
Type-2 innate lymphoid cells in asthma and allergy. Ann Am Thorac Soc (2014) 0.76
Uncontrolled airway inflammation in lung disease represents a defect in counter-regulatory signaling. Future Lipidol (2008) 0.76
Protective effect of soybean oil- or fish oil-rich diets on allergic airway inflammation. J Inflamm Res (2016) 0.75
In Vivo Availability of Pro-Resolving Lipid Mediators in Oxazolone Induced Dermal Inflammation in the Mouse. PLoS One (2015) 0.75
Impact of thrombosis on pulmonary endothelial injury and repair following sepsis. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Lipoxin Signaling in Murine Lung Host Responses to Cryptococcus neoformans Infection. Am J Respir Cell Mol Biol (2016) 0.75
Bigelovii A Protects against Lipopolysaccharide-Induced Acute Lung Injury by Blocking NF-κB and CCAAT/Enhancer-Binding Protein δ Pathways. Mediators Inflamm (2016) 0.75
Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol (2013) 0.75
Natural killer cell-mediated inflammation resolution is disabled in severe asthma. Sci Immunol (2017) 0.75
Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. Mol Aspects Med (2017) 0.75
Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes. Exp Ther Med (2017) 0.75
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med (2004) 14.78
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA (2004) 14.17
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
Letting the genome out of the bottle--will we get our wish? N Engl J Med (2008) 9.10
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. CMAJ (2004) 8.52
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med (2002) 7.99
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet (2004) 7.18
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Data Sharing. N Engl J Med (2016) 5.12
Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med (2004) 5.06
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 5.01
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
Financial associations of authors. N Engl J Med (2002) 4.85
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. N Engl J Med (2005) 4.48
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Clinical trial registration--looking back and moving ahead. N Engl J Med (2007) 4.07
Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors. Ann Intern Med (2016) 3.95
Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol (2002) 3.66
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54
Registry research and medical privacy. N Engl J Med (2004) 3.49
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors. N Engl J Med (2005) 3.44
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2002. A 28-year-old woman with ocular inflammation, fever, and headache. N Engl J Med (2002) 3.31
Physicians and execution. N Engl J Med (2008) 3.30
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
SARS, the Internet, and the Journal. N Engl J Med (2003) 3.16
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12
Sharing Clinical Trial Data--A Proposal from the International Committee of Medical Journal Editors. N Engl J Med (2016) 3.06
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
A sad day for science at the FDA. N Engl J Med (2005) 2.77
Prescriptions, privacy, and the First Amendment. N Engl J Med (2011) 2.75
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Data Sharing and the Journal. N Engl J Med (2016) 2.74
Inappropriate advertising of dietary supplements. N Engl J Med (2003) 2.73
A patient with asthma seeks medical advice in 1828, 1928, and 2012. N Engl J Med (2012) 2.72
Controlling research trials. N Engl J Med (2003) 2.70
A pivotal medical-device case. N Engl J Med (2008) 2.69
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med (2004) 2.62
The FDA, politics, and plan B. N Engl J Med (2004) 2.53
Mechanotransduction through growth-factor shedding into the extracellular space. Nature (2004) 2.48
Uniform format for disclosure of competing interests in ICMJE journals. N Engl J Med (2009) 2.46
Fine particle sources and cardiorespiratory morbidity: an application of chemical mass balance and factor analytical source-apportionment methods. Environ Health Perspect (2008) 2.39
Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med (2003) 2.39
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Uncovering early response of gene regulatory networks in ESCs by systematic induction of transcription factors. Cell Stem Cell (2009) 2.32
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Workgroup report: workshop on source apportionment of particulate matter health effects--intercomparison of results and implications. Environ Health Perspect (2005) 2.29
Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Lancet (2016) 2.25
Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med (2002) 2.24
Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet (2002) 2.23
Believe the data. N Engl J Med (2012) 2.20
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Awake and informed. N Engl J Med (2004) 2.16
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet (2005) 2.15
Public access to biomedical research. N Engl J Med (2004) 2.12
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Sharing individual patient data from clinical trials. N Engl J Med (2015) 2.09
PM source apportionment and health effects: 1. Intercomparison of source apportionment results. J Expo Sci Environ Epidemiol (2006) 2.07
Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06
Legislative myopia on stem cells. N Engl J Med (2003) 2.03
PM source apportionment and health effects. 3. Investigation of inter-method variations in associations between estimated source contributions of PM2.5 and daily mortality in Phoenix, AZ. J Expo Sci Environ Epidemiol (2005) 2.02
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
COX-2 inhibitors--a lesson in unexpected problems. N Engl J Med (2005) 2.01
Expression of concern reaffirmed. N Engl J Med (2006) 1.97
Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Clinical trial registration. BMJ (2007) 1.95
PM source apportionment and health effects: 2. An investigation of intermethod variability in associations between source-apportioned fine particle mass and daily mortality in Washington, DC. J Expo Sci Environ Epidemiol (2005) 1.92
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89